EUR 0.87
(-6.75%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 25.49 Million EUR | 6.95% |
2022 | 23.84 Million EUR | 12.08% |
2021 | 21.27 Million EUR | -28.35% |
2020 | 29.68 Million EUR | 67.35% |
2019 | 17.74 Million EUR | -21.12% |
2018 | 22.49 Million EUR | -55.55% |
2017 | 50.6 Million EUR | 33.12% |
2016 | 38.01 Million EUR | 16.67% |
2015 | 32.57 Million EUR | 4.16% |
2014 | 31.27 Million EUR | -28.32% |
2013 | 43.63 Million EUR | 45.53% |
2012 | 29.98 Million EUR | 1.76% |
2011 | 29.46 Million EUR | 0.22% |
2010 | 29.39 Million EUR | 108.7% |
2009 | 14.08 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 22.98 Million EUR | 0.0% |
2023 FY | 25.49 Million EUR | 6.95% |
2023 Q2 | 33.19 Million EUR | 0.0% |
2023 Q4 | 25.49 Million EUR | 0.0% |
2023 Q3 | 25.49 Million EUR | -23.19% |
2023 Q1 | 33.19 Million EUR | 39.25% |
2022 Q1 | 21.58 Million EUR | 1.48% |
2022 Q3 | 23.84 Million EUR | 10.45% |
2022 Q4 | 23.84 Million EUR | 0.0% |
2022 FY | 23.84 Million EUR | 12.08% |
2022 Q2 | 21.58 Million EUR | 0.0% |
2021 Q2 | 28.45 Million EUR | 0.0% |
2021 Q3 | 21.27 Million EUR | -25.24% |
2021 FY | 21.27 Million EUR | -28.35% |
2021 Q4 | 21.27 Million EUR | 0.0% |
2021 Q1 | 28.45 Million EUR | -4.16% |
2020 Q2 | 22.65 Million EUR | 0.0% |
2020 Q4 | 29.68 Million EUR | 0.0% |
2020 Q1 | 22.65 Million EUR | 27.69% |
2020 Q3 | 29.68 Million EUR | 31.06% |
2020 FY | 29.68 Million EUR | 67.35% |
2019 Q2 | 18.21 Million EUR | 0.0% |
2019 Q4 | 17.74 Million EUR | 0.0% |
2019 Q3 | 17.74 Million EUR | -2.59% |
2019 Q1 | 18.21 Million EUR | -19.03% |
2019 FY | 17.74 Million EUR | -21.12% |
2018 Q2 | 35.65 Million EUR | 0.0% |
2018 FY | 22.49 Million EUR | -55.55% |
2018 Q4 | 22.49 Million EUR | 0.0% |
2018 Q3 | 22.49 Million EUR | -36.93% |
2018 Q1 | 35.65 Million EUR | -29.53% |
2017 Q3 | 50.6 Million EUR | -23.02% |
2017 Q4 | 50.6 Million EUR | 0.0% |
2017 Q1 | 65.73 Million EUR | 72.94% |
2017 Q2 | 65.73 Million EUR | 0.0% |
2017 FY | 50.6 Million EUR | 33.12% |
2016 Q1 | 33.44 Million EUR | 2.66% |
2016 FY | 38.01 Million EUR | 16.67% |
2016 Q4 | 38.01 Million EUR | 0.0% |
2016 Q3 | 38.01 Million EUR | 13.65% |
2016 Q2 | 33.44 Million EUR | 0.0% |
2015 Q4 | 32.57 Million EUR | 0.0% |
2015 FY | 32.57 Million EUR | 4.16% |
2015 Q3 | 32.57 Million EUR | -11.6% |
2015 Q1 | 36.85 Million EUR | 17.83% |
2015 Q2 | 36.85 Million EUR | 0.0% |
2014 Q4 | 31.27 Million EUR | 0.0% |
2014 Q2 | 36.11 Million EUR | 0.0% |
2014 Q1 | 36.11 Million EUR | -17.23% |
2014 FY | 31.27 Million EUR | -28.32% |
2014 Q3 | 31.27 Million EUR | -13.4% |
2013 Q1 | 37.12 Million EUR | 23.84% |
2013 Q2 | 37.12 Million EUR | 0.0% |
2013 Q3 | 43.63 Million EUR | 17.52% |
2013 Q4 | 43.63 Million EUR | 0.0% |
2013 FY | 43.63 Million EUR | 45.53% |
2012 Q4 | 29.98 Million EUR | 0.0% |
2012 Q2 | 33.92 Million EUR | 0.0% |
2012 FY | 29.98 Million EUR | 1.76% |
2011 FY | 29.46 Million EUR | 0.22% |
2011 Q4 | 29.46 Million EUR | 0.0% |
2011 Q2 | 26.09 Million EUR | 0.0% |
2010 Q2 | 30.64 Million EUR | 0.0% |
2010 FY | 29.39 Million EUR | 108.7% |
2010 Q4 | 29.39 Million EUR | 0.0% |
2009 FY | 14.08 Million EUR | 0.0% |
2009 Q4 | 14.08 Million EUR | 0.0% |
2009 Q2 | 30.64 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Boiron SA | 590.2 Million EUR | 95.68% |
Laboratorios Farmaceuticos Rovi, S.A. | 799.88 Million EUR | 96.812% |
Vetoquinol SA | 692.23 Million EUR | 96.316% |
Valneva SE | 469.39 Million EUR | 94.568% |
Nanobiotix S.A. | 93.89 Million EUR | 72.844% |
PHAXIAM Therapeutics S.A. | 51.3 Million EUR | 50.301% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | 17.289% |
BioSenic S.A. | 9.55 Million EUR | -166.754% |
ABIVAX Société Anonyme | 327.06 Million EUR | 92.204% |
Formycon AG | 890.36 Million EUR | 97.136% |